Back to News
Market Impact: 0.3
Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Kairos Pharma announced positive interim efficacy data from its ongoing Phase 2 trial of ENV-105 in combination with apalutamide for patients with metastatic castration-resistant prostate cancer. The announcement provides no numerical efficacy results or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
KAPA0.70
More News
- Why Dangote’s Nigeria Refinery IPO Is Such a Big Deal for Africa
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- Nvidia Is on the Verge of a $6 Trillion Market Value
- Controversial $110 billion mega-merger of Paramount and Warner Bros. finally closes
- What Marvell's rosy long-term guidance means for our AI chip stocks
- GIC Private Ltd, Medline 10% owner, sells over $721m in shares